nach oben

Erschienen in:

01.06.2008

Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes

verfasst von: Margaret Smith, Susan Fawcett, Emanouil Sigalas, Richard Bell, Sophie Devery, Nikolina Andrieska, Ingrid Winship

Erschienen in: Familial Cancer | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

The co-existence of mutations in the BRCA1 and BRCA2 genes is unusual, and to date almost all cases reported have had at least one of the Ashkenazi founder mutations. We report on a family in whom individuals are double heterozygotes for a mutation in BRCA1 and a novel splice site mutation in BRCA2. The phenotypes are discordant, where one sister has had multiple cancers in the BRCA spectrum, while the other is unaffected at 65 years of age. The utility of testing is discussed, and the completion of diagnostic testing despite the finding of a potentially causal mutation is validated.

Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684–1689PubMedCrossRef

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Lui Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, ToninP, Narod S, Bristow Pk, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright I, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef

Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343:692–695

Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265: 2088–2090PubMedCrossRef

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Stratton M (1995) Identification of the breast susceptibility gene BRCA2. Nature 378:789–792PubMedCrossRef

The Breast Cancer Linkage Consortium (1999) Cancer Risks in BRCA2 mutaion carriers. J Natl Cancer Inst 91:1310–1316CrossRef

Welcsh PL, King MC (2001) BRCA1 and BRCA2 in the genetics of breast and ovarian cancer. Hum Mol Genet 10(7):705–713PubMedCrossRef

Hopper JL, Southey MC, Dite GS, Jolley DL, Giles GG, McCredie MR, Easton DF, Venter DJ (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 8:741–747

Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRef

10.

Schubert EL, Metford HC, Dann JL, Argonza RH, Hull J, King MC (1997) BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer. Genet Test 1(1):41–46PubMed

11.

Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, Idenden R, Woodward ER, Lalloo F, Maher ER, Evans DGR (2006) Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet 0:1–6

12.

Leegte B, Van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, Berge A, Leenders EP, Wesseling J, De Hullu J, Hoogerbrugge N, Ligtenberg MJL, Ardern-Jones A, Bancroft E, Salmon E, Barwell J, Eeles R, Oosterwijk JC (2005) Phenotypic expression of double heterzygosity for BRCA1 and BRCA2 germline mutations. J Med Genet 42(3):e20PubMedCrossRef

13.

Choi DH, Lee MH, Haffty BG (2006) Double heterozygotes for non-Caucasian families with mutations in BRCA-1 and BRCA-2 genes. Breast J 12(3):216–220PubMedCrossRef

14.

James PA, Doherty R, Harris M, Mukesh B, Milner A, Young M-A, Scott C (2006) Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. JCO 24(4):707–715CrossRef

15.

Breast cancer information core (BIC) database: http://research.nhgri.nih.gov/bic/

16.

Antoniou A, Pharoah P, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCrossRef

17.

Niell B, Rennert G, Bonner J et al (2004) BRCA 1 and 2 founder mutations and the risk of colorectal cancer. JNCI 96(1):15–21PubMed

Titel: Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes
verfasst von: Margaret Smith
Susan Fawcett
Emanouil Sigalas
Richard Bell
Sophie Devery
Nikolina Andrieska
Ingrid Winship
Publikationsdatum: 01.06.2008
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 2/2008
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-007-9154-8

Springer Medizin

Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers

Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC)

A novel MSH2 germline mutation in a Druze HNPCC family

BRCA1/2 mutation analysis in male breast cancer families from North West England

Sebaceous adenomas in an MYH associated polyposis patient of Indian (Gujarati) origin

Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie